Erlotinib Hydrochloride

Catalog No. Size PriceQuantity
M7656-2 2mg solid $80
M7656-10 10mg solid $240


Erlotinib Hydrochloride (CP-358774 Hydrochloride) inhibits purified EGFR kinase with an IC50 of 2 nM.

Product information

CAS Number: 183319-69-9

Molecular Weight: 429.90

Formula: C22H24ClN3O4





OSI 774



CP-358, 774

Related CAS Number:

183321-74-6 (Erlotinib free base)

248594-19-6 (Erlotinib mesylate)

Chemical Name: N-(3-ethynylphenyl)-6, 7-bis(2-methoxyethoxy)quinazolin-4-amine hydrochloride



InChi: InChI=1S/C22H23N3O4.ClH/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22;/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25);1H

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO: 4 mg/mLwarmed(9.3 mM).

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

Erlotinib HCl potently inhibits EGFR activation in intact cells including HNS human head and neck tumor cells (IC50 20nM), DiFi humancolon cancer cells andMDA MB-468 human breast cancer cells. Erlotinib HCl (1 μM) induces apoptosis in DiFi humancolon cancer cells. Erlotinib inhibits growth of a panel of NSCLC cell lines including A549, H322, H3255, H358 H661, H1650, H1975, H1299, H596 with IC50 ranging from 29 nM to >20 μM. Erlotinib HCl(2 μM) significantly inhibits growth of AsPC-1 and BxPC-3 pancreatic cells. The effects of Erlotinib HCl in combination with gemcitabine are considered additive in KRAS-mutated pancreatic cancer cells. Ten micromolar of Erlotinib HCl inhibits EGFR phospho-rylation at the Y845 (Src-dependent phosphorylation) and Y1068 (auto-phosphorylation) sites. Combination with Erlotinib HCl could down-modulate rapamycin-stimulated Akt activity and produces a synergistic effect on cell growth inhibition.

In Vivo:

At doses of 100 mg/kg, Erlotinib HCl completely prevents EGF-induced autophosphorylation of EGFR in human HN5 tumors growing as xenografts in athymic mice and of the hepatic EGFR of the treated mice. Erlotinib HCl (100 mg/Kg) inhibits H460a and A549 tumor models with 71 and 93% inhibition rate.


  1. Moyer JD, et al. Cancer Res. 1997, 57(21), 4838-4848.
  2. Li T, et al. Clin Cancer Res, 2007, 13(11), 3413-3422.
  3. Ali S, et al. Mol Cancer Ther, 2008, 7(6), 1708-1719.
  4. Buck E, et al. Mol Cancer Ther. 2006, 5(11), 2676-2784.
  5. Higgins B, et al. Anticancer Drugs. 2004, (5), 503-512.
  6. Furugaki K,et al. Oncol Lett. 2010, 1(2), 231-235.
  7. Bago-Horvath Z, et al. 2012, DOI: 10.1159/000337257

Products are for research use only. Not for human use.

Payment & Security

PayPal Venmo

Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.

Estimate shipping

You may also like

Recently viewed